Navigation Links
BioLife Solutions Achieves ISO 13485 Quality Management Systems Certification
Date:12/23/2009

BOTHELL, Wash., Dec. 23 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, today announced that it has successfully completed audits of its quality systems and GMP production facility in Bothell, Washington by BSI Group and has been issued a certification to ISO 13485:2003, an international standard for quality systems supporting the design, development, and manufacture of medical devices.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090814/BIOLIFELOGO)

Mike Rice, BioLife's chairman and CEO, noted, "This achievement is a strategic quality milestone for BioLife. Our growing clinical customer base expects us to set a high bar for the production of our GMP biopreservation media products, since many customer applications include the use of our products as a combined preservative/injection delivery solution for cell-based therapies used to treat cancer, heart failure, and a host of other diseases. We're continuing to enhance the quality footprint of our proprietary, best-in-class HypoThermosol® and CryoStor(TM) biopreservation media products with this certification and updates to our FDA Master Files. Furthermore, we expect to achieve CE Mark conformity for our products in 2010."

In addition to certification to ISO 13485, BioLife's manufacturing facility and quality systems adhere to 21 CFR Part 820 - Quality System Regulation for Good Manufacturing Practices (GMP) of medical devices, 21 CFR Parts 210 and 211 covering GMP for Aseptic Production, Volume 4, EU Guidelines, Annex 1 for the Manufacture of Sterile Medicinal Products, ISO 13408 for aseptic processing of healthcare products, and ISO 14644 for Clean Rooms and Associated Controlled Environments.

Rice continued, "We also successfully completed quality audits of our new GMP production facility and quality systems by several strategic customers and continue to build our profile as the first choice for clinical grade preservation, transport, freezing, and injection media solutions for cell-based products. We're pleased that a growing number of clinical customers have selected our products over commercial competitors or internal formulation of preservation media, often made using lower quality components in sub-optimal processes. We're also very pleased to support our customers with custom packaging and custom formulations of our serum-free, protein-free, pre-formulated biopreservation media products."

About BioLife Solutions

BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death. Comprehensive small animal intravenous safety studies have been completed on HypoThermosol and CryoStor, and both products are supported by US FDA Master Files. BioLife's enabling technology provides research and clinical organizations significantly enhanced post-preservation cell and tissue viability and function. BioLife Solutions is certified to ISO 13485:2003. For more information please visit www.biolifesolutions.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


    Media Relations:                                     Investor Relations:
    Len Hall                                             Matt Clawson
    Allen & Caron Inc                                    Allen & Caron Inc
    (949) 474-4300                                       (949) 474-4300
    len@allencaron.com                                   matt@allencaron.com

SOURCE BioLife Solutions, Inc.


'/>"/>
SOURCE BioLife Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
2. BioLife Solutions Expands Scientific Advisory Board
3. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
4. BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation
5. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
6. BioLife Solutions Credit Facility Increased to $9 Million
7. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
8. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
9. BioLife Solutions Granted European Biopreservation Patent
10. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
11. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... 03, 2016 , ... Microbial genomics leader uBiome is awarding ... been made to Dr. Renato Polimanti of Yale University School of Medicine, who ... Grant proposals have been vetted by the company’s scientific review committee. , ...
(Date:12/2/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski ... and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
Breaking Biology Technology:
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 ... is one of the most crucial aspects of recovery so we need to do ... serious health risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... friends sleep and find a Christmas present that could help them to manage their ... ...
(Date:11/28/2016)... "The biometric system market projected to ... system market is in the growth stage and is ... biometric system market is expected to be valued at ... 16.79% between 2016 and 2022. Government initiative in adoption ... rising use of biometric technology in financial institutes and ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
Breaking Biology News(10 mins):